PT Phapros Tbk (PEHA.JK) Stock

PEHA.JK logo

PT Phapros Tbk

PEHA.JKIndonesia
Healthcare

Company profile

PT Phapros Tbk reported revenue of 940.88 billion IDR for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 221.09 billion IDR, up 10.2% from a year before. Its largest business segment, OGB, brought in 52% of segment revenue in fiscal year 2025. In Q1 2026 it reported net income of 1.53 billion IDR, against a net loss of 5.75 billion IDR a year earlier. Our analysis of its filings shows revenue shrinking from 1.01 trillion IDR in fiscal year 2023 to 940.88 billion IDR in fiscal year 2025, 3.7% a year on average. PT Phapros Tbk reports about 1,263 full-time employees.

What stands out

  • Revenue rose 26.3% in fiscal year 2025, from 744.69 billion IDR in fiscal year 2024, after a fall of 26.6% the year before.
  • It returned to a profit in fiscal year 2025, 28.03 billion IDR, after a net loss of 285.07 billion IDR in fiscal year 2024.

Figures from company filings; latest fiscal year ended December 31, 2025.

About PT Phapros Tbk

PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Generic Drugs Bearing (OCB); and Toll-in segments. It offers OTC drugs, including Antimo Anak, Antimo tablet, Livron B Plex, Becefort Sirop and tablet, Noza, Febrinex, Betafort suspensi, and Hemorogard. The company also provides ethical generic and branded products; and medical devices, as well as toll manufacturing. It also exports its products. The company was founded in 1954 and is headquartered in Jakarta Selatan, Indonesia. PT Phapros Tbk is a subsidiary of PT Kimia Farma Tbk.

Leadership

  • Intan Abdams Katoppo — President Director
  • Ferdinand Troedu — Director of Finance, Risk Management & Human Resources
  • Erfan Rio Prananto — General Manager of Accounting
  • Maraja Jeson Siregar — Director of Marketing & Director
  • Riza Effendi — Head of Internal Control Unit, 56

How much revenue does PT Phapros Tbk make?

PT Phapros Tbk reported 940.88 billion IDR in revenue for fiscal year 2025, up 26.3% from 744.69 billion IDR in fiscal year 2024. In Q1 2026 revenue was 221.09 billion IDR.

What is PT Phapros Tbk's largest business segment?

OGB, with 485.21 billion IDR or 52% of segment revenue in fiscal year 2025. Next: Ethical (26%) and OTC (21%).

What companies are similar to PT Phapros Tbk?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include PT Merck Tbk (MERK.JK), PT Pyridam Farma Tbk (PYFA.JK), PT Indofarma Tbk (INAF.JK).

How has PT Phapros Tbk's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 1.05 trillion IDR; FY2022, 1.17 trillion IDR; FY2023, 1.01 trillion IDR; FY2024, 744.69 billion IDR; FY2025, 940.88 billion IDR.

Has PT Phapros Tbk made a profit in recent years?

Net income by fiscal year: FY2021, 11.07 billion IDR; FY2022, 28.07 billion IDR; FY2023, 5.96 billion IDR; FY2024, a loss of 285.07 billion IDR; FY2025, 28.03 billion IDR. It reported a net loss in 1 of these 5 years.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees1,263
FoundedJun 21, 1954
IPO DateDec 26, 2018
IPO StatusPublic
HeadquartersJakarta Selatan, Indonesia
ExchangeJakarta
TimezoneAsia/Jakarta (WIB)

Contact & Links

Address
Menara Rajawali Lantai 17, Jakarta Selatan, 12950
Phone
62 21 576 2709
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “PT Phapros Tbk (PEHA.JK)”, data as of Mar 31, 2026, https://dataporium.tech/stocks/PEHA.JK

LinkedInLinkedInXXYouTubeYouTube